Acetaminophen 325 mg tablets recalled for incorrect imprinting
Akron Pharma is recalling 14,825 bottles of Acetaminophen 325 mg tablets due to incorrect tablet imprinting affecting lots KDT0124004, KDT0124005, and KDT0124006 (expiring August 31, 2026). No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall for a labeling defect (incorrect tablet imprinting) with no reported illnesses, injuries, or deaths. Class III recalls are typically scored 1-2; this rates as Moderate due to the functional importance of tablet imprinting for correct medication identification.
Plain-English summary
Akron Pharma, Inc. is recalling Acetaminophen 325 mg tablets in 100-tablet bottles. A total of 14,825 bottles are affected. The product was manufactured in Fairfield, New Jersey (NDC 71399-8014-01).
The recall is being issued due to a labeling defect: the tablets are imprinted with wrong identification markings. The affected lot numbers are KDT0124004, KDT0124005, and KDT0124006, which expire on August 31, 2026.
The product was distributed nationwide throughout the United States. No illnesses or injuries have been reported in connection with this defect.
The recalled product
- Product
- Acetaminophen, 325 mg Tablets, 100 Tablets per bottle, Akron Pharma, Manufactured for: Akron Pharma Inc., Fairfield, NJ 07034, NDC 71399-8014-01.
- Manufacturer
- Akron Pharma, Inc.
- Category
- Drug — Acetaminophen / Tablet
- Hazard
- mis-labeling
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #s: KDT0124004
- KDT0124005
- KDT0124006
- Exp 08/31/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27